dataesr/scientific-paragraphs-categorization huggingface dataset:
gov/search?id=%22NCT00097435%22 https://clinicaltrials. gov/search?id=%22NCT03537599%22 https://clinicaltrials. gov/search?id=%22NCT04922723%22 https://clinicaltrials. gov/search?id=%22NCT03177460%22 https://clinicaltrials. gov/search?id=%22NCT03701321%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT00577694%22 https://clinicaltrials. gov/search?id=%22NCT00669890%22 https://clinicaltrials. gov/search?id=%22NCT04915612%22 https://clinicaltrials. gov/search?id=%22NCT03568994%22 https://clinicaltrials. gov/search?id=%22NCT03932318%22 https://clinicaltrials. gov/search?id=%22NCT01756677%22 https://clinicaltrials. gov/search?id=%22NCT02998047%22 https://clinicaltrials. gov/search?id=%22NCT00283114%22 https://clinicaltrials. gov/search?id=%22NCT03069703%22 https://clinicaltrials.
gov/search?id=%22NCT01419561%22 https://clinicaltrials. gov/search?id=%22NCT00537290%22 https://clinicaltrials. gov/search?id=%22NCT01686165%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT03023423%22 https://clinicaltrials. gov/search?id=%22NCT02258854%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT03484702%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT00006072%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297236 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LISOCABTAGENE MARALEUCEL RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Gene B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0000685 EFO_0004599 Binding agent EFO_0000095 Binding agent EFO_0003144 acute graft vs.
host disease rheumatoid arthritis chronic lymphocytic leukemia heart failure 1 Recruiting 2 Suspended 1 Recruiting 2 Not yet recruiting https://clinicaltrials. gov/search?id=%22NCT04204980%22 https://clinicaltrials. gov/search?id=%22NCT00777816%22 https://clinicaltrials. gov/search?id=%22NCT03331198%22 https://clinicaltrials. gov/search?id=%22NCT03332888%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297236 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LISOCABTAGENE MARALEUCEL RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Gene B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0001359 EFO_0005952 Binding agent EFO_0000220 Binding agent EFO_0003780 non-Hodgkins lymphoma type I diabetes mellitus acute lymphoblastic leukemia Behcet's syndrome 1 Active, not recruiting 2 Completed 1 Recruiting 2 Completed https://clinicaltrials.
gov/search?id=%22NCT01592370%22 https://clinicaltrials. gov/search?id=%22NCT00998699%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT03743246%22 https://clinicaltrials. gov/search?id=%22NCT00664599%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297236 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LISOCABTAGENE MARALEUCEL RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Gene B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0002506 EFO_0006475 Binding agent EFO_0000403 Binding agent EFO_0003840 plasma cell leukemia osteoarthritis diffuse large B-cell lymphoma chronic progressive multiple sclerosis 1 Withdrawn 2 Completed 1 Recruiting 2 Completed https://clinicaltrials.
gov/search?id=%22NCT03591744%22 https://clinicaltrials. gov/search?id=%22NCT01882491%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT02631044%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT02545959%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297236 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LISOCABTAGENE MARALEUCEL RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Gene B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0003894 EFO_1001051 Binding agent EFO_1001469 Binding agent EFO_0003860 mycosis fungoides acne Mantle cell lymphoma pancreatic neoplasm 1 Suspended 2 Completed 1 Recruiting 2 Completed https://clinicaltrials.
gov/search?id=%22NCT03432741%22 https://clinicaltrials. gov/search?id=%22NCT01498874%22 https://clinicaltrials. gov/search?id=%22NCT02631044%22 https://clinicaltrials. gov/search?id=%22NCT00001805%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297236 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LISOCABTAGENE MARALEUCEL RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Gene B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0009672 MONDO_0019465 Binding agent MONDO_0018906 Binding agent EFO_0003869 nodal marginal zone B-cell lymphoma inner ear disease follicular lymphoma breast neoplasm 1 Suspended 2 Completed 1 Recruiting 2 Completed https://clinicaltrials.
gov/search?id=%22NCT03432741%22 https://clinicaltrials. gov/search?id=%22NCT01950312%22 https://clinicaltrials. gov/search?id=%22NCT02631044%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT00001805%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297778 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LONCASTUXIMAB TESIRINE RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Antibody B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator HP_0000999 Orphanet_85443 Binding agent EFO_1001938 Binding agent EFO_0003897 AL amyloidosis Pyoderma B-cell non-Hodgkins lymphoma stomach neoplasm 1 Recruiting 2 Completed 4 2 Completed https://clinicaltrials.
gov/search?id=%22NCT03283917%22 https://clinicaltrials. gov/search?id=%22NCT01882504%22 http://www. accessdata. fda. gov/drugsatfda_docs/label/2021/761196s000lbl. pdf https://clinicaltrials. gov/search?id=%22NCT00001805%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297778 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LONCASTUXIMAB TESIRINE RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Antibody B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0001360 EFO_0000349 Binding agent MONDO_0018906 Binding agent EFO_0003898 clear cell renal carcinoma type II diabetes mellitus follicular lymphoma ankylosing spondylitis 0 Active, not recruiting 1 Completed 2 Recruiting 2 Unknown status https://clinicaltrials.
gov/search?id=%22NCT03473730%22 https://clinicaltrials. gov/search?id=%22NCT00513214%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT04699461%22 https://clinicaltrials. gov/search?id=%22NCT00432653%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297778 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LONCASTUXIMAB TESIRINE RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Antibody B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator EFO_0003780 EFO_0000403 Binding agent EFO_0000096 Binding agent EFO_0004244 diffuse large B-cell lymphoma Behcet's syndrome neoplasm of mature B-cells interstitial lung disease 0 Recruiting 1 Withdrawn 1 Not yet recruiting 2 Withdrawn https://clinicaltrials.
gov/search?id=%22NCT04139304%22 https://clinicaltrials. gov/search?id=%22NCT01211977%22 https://clinicaltrials. gov/search?id=%22NCT04970901%22 https://clinicaltrials. gov/search?id=%22NCT02789397%22 CHEMBL1743007 CHEMBL1743026 CHEMBL4297778 CHEMBL1201576 DARATUMUMAB GEVOKIZUMAB LONCASTUXIMAB TESIRINE RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta negative allosteric modulator Antibody B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Negative allosteric modulator MONDO_0001718 EFO_0006544 Binding agent EFO_0000220 Binding agent EFO_0004254 bladder transitional cell carcinoma scleritis acute lymphoblastic leukemia membranous glomerulonephritis 0 Active, not recruiting 1 Completed 1 Terminated 2 Completed https://clinicaltrials.
gov/search?id=%22NCT03473730%22 https://clinicaltrials. gov/search?id=%22NCT01835132%22 https://clinicaltrials. gov/search?id=%22NCT02669264%22 https://clinicaltrials. gov/search?id=%22NCT01180036%22 CHEMBL3545371 CHEMBL2108707 CHEMBL4297778 CHEMBL1201576 DENINTUZUMAB MAFODOTIN GLEMBATUMUMAB LONCASTUXIMAB TESIRINE RITUXIMAB Antibody B-lymphocyte antigen CD19 binding agent Antibody Transmembrane glycoprotein NMB binding agent Antibody B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Binding agent Binding agent EFO_0000220 EFO_0000756 EFO_0000403 EFO_0004255 acute lymphoblastic leukemia melanoma diffuse large B-cell lymphoma nephrotic syndrome 1 Completed 1 Completed 1 Not yet recruiting 2 Recruiting https://clinicaltrials. gov/search?id=%22NCT01786135%22 https://clinicaltrials.
gov/search?id=%22NCT00412828%22 https://clinicaltrials. gov/search?id=%22NCT04974996%22 https://clinicaltrials. gov/search?id=%22NCT04783675%22,https://clinicaltrials. gov/search?id=%22N CHEMBL3545371 CHEMBL2108707 CHEMBL3545131 CHEMBL4594518 CHEMBL1201576 DENINTUZUMAB MAFODOTIN GLEMBATUMUMAB ISATUXIMAB LUTIKIZUMAB RITUXIMAB Antibody B-lymphocyte antigen CD19 binding agent Antibody Transmembrane glycoprotein NMB binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta inhibitor Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Inhibitor Inhibitor Binding agent EFO_0000309 MONDO_0007254 EFO_0000203 EFO_1000789 EFO_0004288 Burkitts lymphoma breast cancer monoclonal gammopathy osteoarthritis, hand colonic neoplasm 1 Completed 1 Completed 2 Not yet recruiting 2 Completed 2 Completed https://clinicaltrials.
gov/search?id=%22NCT01786135%22 https://clinicaltrials. gov/search?id=%22NCT00704158%22 https://clinicaltrials. gov/search?id=%22NCT04614558%22 https://clinicaltrials. gov/search?id=%22NCT02384538%22 https://clinicaltrials. gov/search?id=%22NCT00001805%22 CHEMBL3545371 CHEMBL1743028 CHEMBL3545131 CHEMBL4594518 CHEMBL1201576 DENINTUZUMAB MAFODOTIN GLEMBATUMUMAB VEDOTIN ISATUXIMAB LUTIKIZUMAB RITUXIMAB Antibody B-lymphocyte antigen CD19 binding agent Antibody Transmembrane glycoprotein NMB binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Interleukin-1 beta inhibitor Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Inhibitor Inhibitor Binding agent EFO_0000403 EFO_0000637 EFO_0000220 EFO_0002506 EFO_0004540 diffuse large B-cell lymphoma osteosarcoma acute lymphoblastic leukemia osteoarthritis chronic fatigue syndrome 1 Completed 2 Active, not recruiting 2 Recruiting 1 Completed 2 Completed https://clinicaltrials.
gov/search?id=%22NCT01786135%22 https://clinicaltrials. gov/search?id=%22NCT02487979%22 https://clinicaltrials. gov/search?id=%22NCT03860844%22 https://clinicaltrials. gov/search?id=%22NCT01668511%22 https://clinicaltrials. gov/search?id=%22NCT00848692%22 CHEMBL3545371 CHEMBL1743028 CHEMBL3545131 CHEMBL2109447 CHEMBL1201576 DENINTUZUMAB MAFODOTIN GLEMBATUMUMAB VEDOTIN ISATUXIMAB LYM-1 RITUXIMAB Antibody B-lymphocyte antigen CD19 binding agent Antibody Transmembrane glycoprotein NMB binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody HLA class II histocompatibility antigen, DRB1-10 beta chain other Other Binding agent Binding agent Inhibitor Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_1001469 EFO_0000756 EFO_0000222 EFO_0000574 EFO_0004599 Mantle cell lymphoma melanoma acute myeloid leukemia lymphoma acute graft vs.
host disease 1 Completed 2 Terminated 2 Recruiting 1 Unknown status 2 Completed https://clinicaltrials. gov/search?id=%22NCT01786135%22 https://clinicaltrials. gov/search?id=%22NCT02302339%22 https://clinicaltrials. gov/search?id=%22NCT03860844%22 https://clinicaltrials. gov/search?id=%22NCT00009776%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT00771875%22 CHEMBL3545371 CHEMBL1743028 CHEMBL3545131 CHEMBL2109267 CHEMBL1201576 DENINTUZUMAB MAFODOTIN GLEMBATUMUMAB VEDOTIN ISATUXIMAB M195 RITUXIMAB Antibody B-lymphocyte antigen CD19 binding agent Antibody Transmembrane glycoprotein NMB binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Myeloid cell surface antigen CD33 other Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Inhibitor Other Binding agent MONDO_0018906 EFO_1000616 EFO_0003073 EFO_0000198 EFO_0005761 follicular lymphoma Uveal Melanoma asymptomatic myeloma myelodysplastic syndrome lupus nephritis 1 Completed 2 Completed 2 Recruiting 1 Completed 2 Completed https://clinicaltrials.
gov/search?id=%22NCT01786135%22 https://clinicaltrials. gov/search?id=%22NCT02363283%22 https://clinicaltrials. gov/search?id=%22NCT02960555%22 https://clinicaltrials. gov/search?id=%22NCT00014495%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT02260934%22 CHEMBL4594579 CHEMBL1743028 CHEMBL3545131 CHEMBL2109267 CHEMBL1201576 FELZARTAMAB GLEMBATUMUMAB VEDOTIN ISATUXIMAB M195 RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Transmembrane glycoprotein NMB binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Myeloid cell surface antigen CD33 other Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Binding agent Inhibitor Other Binding agent EFO_0003086 EFO_0000708 EFO_0005592 EFO_0000565 EFO_0007208 kidney disease squamous cell lung carcinoma T-cell leukemia leukemia Churg-Strauss syndrome 2 Not yet recruiting 1 Terminated 2 Terminated 1 Completed 2 Terminated https://clinicaltrials.
gov/search?id=%22NCT04893096%22 https://clinicaltrials. gov/search?id=%22NCT02713828%22 https://clinicaltrials. gov/search?id=%22NCT02999633%22 https://clinicaltrials. gov/search?id=%22NCT00014495%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT00424749%22 CHEMBL4594579 CHEMBL1743028 CHEMBL3545131 CHEMBL2109267 CHEMBL1201576 FELZARTAMAB GLEMBATUMUMAB VEDOTIN ISATUXIMAB M195 RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Transmembrane glycoprotein NMB binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Myeloid cell surface antigen CD33 other Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Binding agent Inhibitor Other Binding agent MONDO_0002462 MONDO_0007254 MONDO_0044917 EFO_0004251 EFO_0007332 glomerulonephritis breast cancer T-lymphoblastic lymphoma myeloproliferative disorder Japanese encephalitis 2 Recruiting 0 Withdrawn 2 Terminated 1 Completed 2 Not yet recruiting https://clinicaltrials.
gov/search?id=%22NCT04733040%22 https://clinicaltrials. gov/search?id=%22NCT03473691%22 https://clinicaltrials. gov/search?id=%22NCT02999633%22 https://clinicaltrials. gov/search?id=%22NCT00014495%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT03274375%22 CHEMBL4594579 CHEMBL2109509 CHEMBL3545131 CHEMBL2109337 CHEMBL1201576 FELZARTAMAB HCBE-11 ISATUXIMAB MDX-1342 RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Tumor necrosis factor receptor superfamily member 3 agonist Agonist Inhibitor Antibody Lymphocyte differentiation antigen CD38 inhibitor Inhibitor Antibody B-lymphocyte antigen CD19 binding agent Binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0001378 EFO_0000616 EFO_0000540 EFO_0000095 EFO_0007359 multiple myeloma neoplasm immune system disease chronic lymphocytic leukemia mast-cell leukemia 1 Completed 1 Terminated 1 Recruiting 1 Completed 2 Completed https://clinicaltrials.
gov/search?id=%22NCT01421186%22 https://clinicaltrials. gov/search?id=%22NCT00105170%22 https://clinicaltrials. gov/search?id=%22NCT04294459%22 https://clinicaltrials. gov/search?id=%22NCT00593944%22 https://clinicaltrials. gov/search?id=%22NCT00186628%22 CHEMBL4594579 CHEMBL1201606 CHEMBL3545131 CHEMBL2109337 CHEMBL1201576 FELZARTAMAB IBRITUMOMAB TIUXETAN ISATUXIMAB MDX-1342 RITUXIMAB Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody B-lymphocyte antigen CD19 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Binding agent Inhibitor Binding agent Binding agent EFO_0004254 EFO_0000096 EFO_0000574 EFO_0000685 EFO_0009538 membranous glomerulonephritis neoplasm of mature B-cells lymphoma rheumatoid arthritis chronic inflammatory demyelinating polyneuropathy 2 Not yet recruiting 1 Recruiting 2 Completed 1 Active, not recruiting 1 Completed https://clinicaltrials.
gov/search?id=%22NCT04145440%22 https://clinicaltrials. gov/search?id=%22NCT00138086%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT03769181%22 https://clinicaltrials. gov/search?id=%22NCT00639834%22 https://clinicaltrials. gov/search?id=%22NCT04480450%22 CHEMBL3990038 CHEMBL1201606 CHEMBL3545131 CHEMBL2109391 CHEMBL1201576 FLOTETUZUMAB IBRITUMOMAB TIUXETAN ISATUXIMAB MDX-447 RITUXIMAB Antibody T cell surface glycoprotein CD3 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody High affinity immunoglobulin gamma Fc receptor I cross-linking agent Binding agent Binding agent Inhibitor Cross-linking agent EFO_1000158 EFO_0000222 MONDO_0013730 EFO_0000616 Antibody B-lymphocyte antigen CD20 binding agent Binding agent EFO_0010580 acute myeloid leukemia graft versus host disease neoplasm Central Nervous System Neoplasm blastic plasmacytoid dendritic cell neoplasm 1 Recruiting 2 Active, not recruiting 1 Active, not recruiting 1 Completed 2 Recruiting https://clinicaltrials.
gov/search?id=%22NCT02152956%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT00577278%22 https://clinicaltrials. gov/search?id=%22NCT03637764%22 https://clinicaltrials. gov/search?id=%22NCT00005813%22 https://clinicaltrials. gov/search?id=%22NCT04216524%22 CHEMBL1743020 CHEMBL1201606 CHEMBL3545131 CHEMBL4297833 CHEMBL1201576 FORALUMAB IBRITUMOMAB TIUXETAN ISATUXIMAB MEZAGITAMAB RITUXIMAB Antibody T cell surface glycoprotein CD3 inhibitor Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Lymphocyte differentiation antigen CD38 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Binding agent Inhibitor Binding agent Binding agent EFO_0000384 EFO_0000095 EFO_0001378 EFO_0004991 EFO_1000318 Crohn's disease chronic lymphocytic leukemia multiple myeloma Myasthenia gravis Langerhans Cell Histiocytosis 1 Completed 1 Terminated 1 Active, not recruiting 2 Recruiting 2 Recruiting https://clinicaltrials.
gov/search?id=%22NCT00630643%22 https://clinicaltrials. gov/search?id=%22NCT00012298%22 https://clinicaltrials. gov/search?id=%22NCT02514668%22,https://clinicaltrials. gov/search?id=%22N https://clinicaltrials. gov/search?id=%22NCT04159805%22 https://clinicaltrials. gov/search?id=%22NCT03096782%22 CHEMBL1743020 CHEMBL1201606 CHEMBL3545131 CHEMBL4297833 CHEMBL1201576 FORALUMAB IBRITUMOMAB TIUXETAN ISATUXIMAB MEZAGITAMAB RITUXIMAB Antibody T cell surface glycoprotein CD3 inhibitor Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Lymphocyte differentiation antigen CD38 binding agent Antibody B-lymphocyte antigen CD20 binding agent Inhibitor Binding agent Inhibitor Binding agent Binding agent EFO_0004599 EFO_0000183 EFO_0001642 EFO_0007160 EFO_1000749 acute graft vs.
host disease Hodgkins lymphoma lymphoid neoplasm autoimmune thrombocytopenic purpura pemphigus 1 Completed 1 Terminated 1 Active, not recruiting 2 Recruiting 2 Recruiting https://clinicaltrials. gov/search?id=%22NCT00805909%22 https://clinicaltrials. gov/search?id=%22NCT00036855%22 https://clinicaltrials. gov/search?id=%22NCT01084252%22 https://clinicaltrials. gov/search?id=%22NCT04278924%22 https://clinicaltrials. gov/search?id=%22NCT04400994%22 CHEMBL2108342 CHEMBL1201606 CHEMBL3545131 CHEMBL4297833 CHEMBL1201576 GEMTUZUMAB IBRITUMOMAB TIUXETAN ISATUXIMAB MEZAGITAMAB RITUXIMAB Antibody Myeloid cell surface antigen CD33 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Lymphocyte differentiation antigen CD38 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Inhibitor Binding agent Binding agent EFO_0000222 EFO_0000191 EFO_1001264 EFO_0001378 EFO_1000783 acute myeloid leukemia MALT lymphoma Anemia, Hemolytic, Autoimmune multiple myeloma diabetic neuropathy 3 Completed 1 Terminated 1 Recruiting 1 Recruiting 2 Completed https://clinicaltrials.
gov/search?id=%22NCT00136084%22 https://clinicaltrials. gov/search?id=%22NCT00012298%22 https://clinicaltrials. gov/search?id=%22NCT04661033%22 https://clinicaltrials. gov/search?id=%22NCT04776018%22 https://clinicaltrials. gov/search?id=%22NCT00050245%22 CHEMBL1201506 CHEMBL1201606 CHEMBL3545131 CHEMBL4297833 CHEMBL1201576 GEMTUZUMAB OZOGAMICIN IBRITUMOMAB TIUXETAN ISATUXIMAB MEZAGITAMAB RITUXIMAB Antibody Myeloid cell surface antigen CD33 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Lymphocyte differentiation antigen CD38 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Inhibitor Binding agent Binding agent EFO_0000616 EFO_0000309 EFO_1001951 EFO_0002690 EFO_1000784 neoplasm Burkitts lymphoma colorectal carcinoma systemic lupus erythematosus microscopic polyangiitis 4 1 Completed 1 Recruiting 1 Recruiting 2 Completed http://www.
whocc. no/atc_ddd_index/?code=L01XC05 https://clinicaltrials. gov/search?id=%22NCT00064246%22 https://clinicaltrials. gov/search?id=%22NCT03555149%22 https://clinicaltrials. gov/search?id=%22NCT03724916%22 https://clinicaltrials. gov/search?id=%22NCT00104299%22 CHEMBL1201506 CHEMBL1201606 CHEMBL3545131 CHEMBL4297833 CHEMBL1201576 GEMTUZUMAB OZOGAMICIN IBRITUMOMAB TIUXETAN ISATUXIMAB MEZAGITAMAB RITUXIMAB Antibody Myeloid cell surface antigen CD33 binding agent Antibody B-lymphocyte antigen CD20 binding agent Antibody Lymphocyte differentiation antigen CD38 inhibitor Antibody Lymphocyte differentiation antigen CD38 binding agent Antibody B-lymphocyte antigen CD20 binding agent Binding agent Binding agent Inhibitor Binding agent Binding agent EFO_0000220 EFO_0000403 Orphanet_85443 EFO_0005140 EFO_1000868 acute lymphoblastic leukemia diffuse large B-cell lymphoma AL amyloidosis autoimmune disease chronic inflammatory demyelinating polyradiculoneuropathy 2 Active, not recruiting 2 Terminated 1 Terminated 1 Recruiting 1 Completed https://clinicaltrials.